AFT Pharmaceuticals First Half 2025 Earnings: NZ$0.02 loss per share (vs NZ$0.02 profit in 1H 2024)

Simply Wall St · 6d ago

AFT Pharmaceuticals (NZSE:AFT) First Half 2025 Results

Key Financial Results

  • Revenue: NZ$86.7m (up 3.7% from 1H 2024).
  • Net loss: NZ$2.19m (down by 220% from NZ$1.82m profit in 1H 2024).
  • NZ$0.02 loss per share (down from NZ$0.02 profit in 1H 2024).
earnings-and-revenue-growth
NZSE:AFT Earnings and Revenue Growth November 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

AFT Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Pharmaceuticals industry in Oceania.

Performance of the market in New Zealand.

The company's shares are up 22% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on AFT Pharmaceuticals' balance sheet health.